COMPARATIVE COMPETITION LAW IN HEALTHCARE: A REVIEW OF U.S. AND INDONESIAN REGULATORY APPROACHES

Raymond R. Tjandrawinata

doi:10.46799/ijssr.v5i3.1210

Authors

Raymond R. Tjandrawinata Universitas Katolik Atma Jaya

DOI:

https://doi.org/10.46799/ijssr.v5i3.1210

Keywords:

competition law, healthcare antitrust, Indonesia regulation, pharmaceutical pricing, U.S. enforcement

Abstract

The rapid expansion of digital health services and telemedicine introduces new dimensions to competition law enforcement in healthcare. This paper explores strategic recommendations to enhance Indonesia's competition law in healthcare by focusing on strengthening regulatory institutions, improving judicial consistency, fostering private enforcement mechanisms, and developing targeted policies for emerging digital health markets. This study employs a comparative legal analysis approach, integrating qualitative and normative research methods, to examine the effectiveness of existing competition law frameworks governing healthcare in the United States and Indonesia, identifying best practices, challenges, and opportunities for improvement. The findings reveal stark contrasts in competition law enforced between the two countries, particularly in market concentration, regulatory oversight, judicial intervention, and private litigation mechanisms. By adopting a framework that fosters industry sustainability while preventing anti-competitive behavior, Indonesia can create a more competitive, innovative, and accessible healthcare system that benefits both pharmaceutical companies and consumers alike.

References

Alfiani, F. R. N., & Santiago, F. (2024). A Comparative Analysis of Artificial Intelligence Regulatory Law in Asia, Europe, and America. SHS Web of Conferences, 204, 07006. https://doi.org/10.1051/shsconf/202420407006

Baker, J. B. (2019). The antitrust paradigm: Restoring a competitive economy. Harvard University Press.

Cambaza, E. M. (2024). Theranos: the Ethics of Innovation and Deception in Healthcare Technology. REVES - Revista Relações Sociais, 7(2), 19792. https://doi.org/10.18540/revesvl7iss2pp19792

Carreyrou, J. (2018). Bad blood: Secrets and lies in a Silicon Valley startup. Knopf.

Chakraborty, D. (2024). Merger Control and Competition Policy. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.4865812

Congressional Research Service. (2024). The role of patents and regulatory exclusivities in drug pricing.

CSDH. (2008). Closing the gap in a generation: Health equity through action on the social determinants of health. Final report of the Commission on Social Determinants of Health. WHO.

Dewayanti, I., & Firdaus, S. U. (2023). Telemedicine in Indonesia: Perspective of Ethic, Discipline and Law. Proceedings of the International Conference for Democracy and National Resilience 2022 (ICDNR 2022). https://doi.org/10.2991/978-2-494069-75-6_2

Dewi, R., Timori, H. P., S, Moh. K. A., Zakariya, A., Putri, A. A., Taena, M., & Ramadhanty, A. E. (2024). PERAN KOMISI PENGAWAS PERSAINGAN USAHA SEBAGAI WASIT SEKALIGUS HAKIM DALAM EKONOMI. Collegium Studiosum Journal, 7(2), 481–496. https://doi.org/10.56301/csj.v7i2.1417

Djolov, G. (2013). The herfindahl-hirschman index as a decision guide to business concentration: A statistical exploration. Journal of Economic and Social Measurement, 38(3). https://doi.org/10.3233/JEM-130379

Drury, P., & Lazuardi, L. (2021). Telehealth and digital inclusion in Indonesia: Full report. HEART Resources.

Federal Trade Commission. (2023). Biopharmaceutical giant Amgen to settle FTC, state challenges to its Horizon Therapeutics acquisition. Federal Trade Commission.

Feldman, R., Fulton, B. D., Godwin, J. R., & Scheffler, R. M. (2022). Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation. Journal of Health Politics, Policy and Law, 47(5). https://doi.org/10.1215/03616878-9978131

Galasso, A., & Luo, H. (2024). Product Liability Litigation and Innovation: Evidence from Medical Devices. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.4758138

Gaynor, M., & Ginsburg, P. B. (2017). Making Health Care Markets Work: Competition Policy for Health Care. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.2964912

Glick, M. A., & Bush, D. (2023). The Chicago School, the Post Chicago School, and the New Brandeisian Schools of Antitrust: Who Is Right in Light of Modern Economics? SSRN Electronic Journal. https://doi.org/10.2139/ssrn.4417509

Grabowski, H., Long, G., Mortimer, R., & Bilginsoy, M. (2021). Continuing trends in U.S. brand-name and generic drug competition. Journal of Medical Economics, 24(1). https://doi.org/10.1080/13696998.2021.1952795

Gu, A. Y. (2022). DOJ’s challenge of the UnitedHealth and Change Healthcare merger: What went wrong and what does it mean? The Source on Healthcare Price & Competition.

Hovenkamp, H. (2020). Federal antitrust policy: The law of competition and its practice. West Academic.

Javaid, M., Haleem, A., & Singh, R. P. (2024). Health informatics to enhance the healthcare industry’s culture: An extensive analysis of its features, contributions, applications and limitations. Informatics and Health, 1(2), 123–148. https://doi.org/10.1016/j.infoh.2024.05.001

Miller, E. J. (2022). Amended declaration of Eric J. Miller in support of direct purchaser plaintiffs’ motion for preliminary approval of settlements with Sun and Taro defendants.

Murphy, N. (2024). Trends and consequences in health insurer consolidation. Center for American Progress.

Noonan, K. E. (2015). The role of regulatory agencies and intellectual property: Part I. Cold Spring Harbor Perspectives in Medicine, 5(7). https://doi.org/10.1101/cshperspect.a020800

Paluttri, S. (2023). Comparative approach in public health social security: a legal case study of the Indonesian, France, and Singapore health systems. International Journal of Human Rights in Healthcare. https://doi.org/10.1108/IJHRH-03-2023-0020

Pasaribu, M. S. M. (2016). Challenges of Indonesian competition law and some suggestions for improvement (2016–04; ERIA Discussion Paper Series).

Prasad, V., & Mailankody, S. (2017). Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Internal Medicine, 177(11). https://doi.org/10.1001/jamainternmed.2017.3601

Rachmawati, E., Umniyatun, Y., Kurniawan, D. W., Nurmansyah, M. I., Pakkanna, M., Nurjuman, H., Budiarto, S., & Gohardi, V. S. (2024). ANALYSIS OF THE MARKET STRUCTURE OF HOSPITAL INDUSTRY IN INDONESIA. Jurnal Administrasi Kesehatan Indonesia, 12(1), 37–48. https://doi.org/10.20473/jaki.v12i1.2024.37-48

Santoso, D. B., Suprapto, E., Zakaria, R. A., Kusumaningrum, H. A., & Jamil, H. (2023). Analysis of banking competition in Indonesia and its impact on profitability: Structure conduct performance (SCP) approach. Journal of Innovation in Business and Economics, 7(01). https://doi.org/10.22219/jibe.v7i01.27156

Satibi, S., Kirana, P. L. K., Aziza, P. M., Hutasoit, M., & Pribadi, P. (2022). Analysis of e-catalogue drug prices in the era of Universal Health Coverage in the Indonesian pharmaceutical industry. Pharmacia, 69(2). https://doi.org/10.3897/pharmacia.69.e83068

Sawyer, L. P. (2019). U.S. antitrust law and policy in historical perspective (19–110).

Tewari, A. (2024). A Critical Evaluation of India’s Proposed Digital Competition Act. Competition Commission of India Journal on Competition Law and Policy, 79–104. https://doi.org/10.54425/ccijoclp.v5.197

U.S. Department of Justice. (2022). Justice Department sues to block United Health Group’s acquisition of Change Healthcare. U.S. Department of Justice.

U.S. Department of State. (2024). 2024 investment climate statements: Indonesia. U.S. Department of State.

U.S. Supreme Court. (2013). Federal Trade Commission v. Actavis, Inc., et al., 570 U.S. 136.